DE60023520D1 - Flüssiges hochvisköses system mit gesteuerter freisetzung und medizinische oder chirurgische vorrichtung - Google Patents

Flüssiges hochvisköses system mit gesteuerter freisetzung und medizinische oder chirurgische vorrichtung

Info

Publication number
DE60023520D1
DE60023520D1 DE60023520T DE60023520T DE60023520D1 DE 60023520 D1 DE60023520 D1 DE 60023520D1 DE 60023520 T DE60023520 T DE 60023520T DE 60023520 T DE60023520 T DE 60023520T DE 60023520 D1 DE60023520 D1 DE 60023520D1
Authority
DE
Germany
Prior art keywords
medical
controlled release
solvent
surgical device
high visible
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60023520T
Other languages
English (en)
Other versions
DE60023520T2 (de
Inventor
W Gibson
A Sullivan
G Middleton
J Tipton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Durect Corp
Original Assignee
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Durect Corp filed Critical Durect Corp
Application granted granted Critical
Publication of DE60023520D1 publication Critical patent/DE60023520D1/de
Publication of DE60023520T2 publication Critical patent/DE60023520T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0015—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0026—Sprayable compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y10T428/2985—Solid-walled microcapsule from synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Materials Engineering (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Birds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Saccharide Compounds (AREA)
  • Prostheses (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
DE60023520T 1999-08-27 2000-08-24 Flüssiges hochviskoses system mit gesteuerter freisetzung und medizinische oder chirurgische vorrichtung Expired - Lifetime DE60023520T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US385107 1999-08-27
US09/385,107 US6413536B1 (en) 1995-06-07 1999-08-27 High viscosity liquid controlled delivery system and medical or surgical device
PCT/US2000/023270 WO2001015734A2 (en) 1999-08-27 2000-08-24 High viscosity liquid controlled delivery system and medical or surgical device

Publications (2)

Publication Number Publication Date
DE60023520D1 true DE60023520D1 (de) 2005-12-01
DE60023520T2 DE60023520T2 (de) 2006-07-27

Family

ID=23520037

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60023520T Expired - Lifetime DE60023520T2 (de) 1999-08-27 2000-08-24 Flüssiges hochviskoses system mit gesteuerter freisetzung und medizinische oder chirurgische vorrichtung

Country Status (9)

Country Link
US (3) US6413536B1 (de)
EP (1) EP1212092B1 (de)
JP (2) JP4276807B2 (de)
AT (1) ATE307611T1 (de)
AU (3) AU7331900A (de)
CA (1) CA2382540C (de)
DE (1) DE60023520T2 (de)
ES (1) ES2254219T3 (de)
WO (1) WO2001015734A2 (de)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
CA2336703A1 (en) * 1998-07-10 2000-01-20 The University Of Sydney Prophylactic treatments of neovascularisation in macular degeneration
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
AUPQ496500A0 (en) * 2000-01-06 2000-02-03 University Of Sydney, The Kit
WO2001078683A2 (en) * 2000-04-19 2001-10-25 Genentech, Inc. Sustained release formulations comprising growth hormone
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
US9080146B2 (en) 2001-01-11 2015-07-14 Celonova Biosciences, Inc. Substrates containing polyphosphazene as matrices and substrates containing polyphosphazene with a micro-structured surface
CA2440387A1 (en) * 2001-03-23 2002-10-03 Durect Corporation Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
PT1397155E (pt) * 2001-06-21 2015-12-07 Genentech Inc Formulação de libertação sustentada
US7357949B2 (en) * 2001-12-21 2008-04-15 Agion Technologies Inc. Encapsulated inorganic antimicrobial additive for controlled release
US20030118658A1 (en) * 2001-12-21 2003-06-26 Trogolo Jeffrey A. High aspect ratio encapsulated inorganic antimicrobial additive for controlled release
EP1532974B1 (de) 2002-03-12 2008-12-17 Galderma Research & Development Zusammensetzung enthaltend 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoesäure zur Behandlung dermatologischer Erkrankungen
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US8075585B2 (en) * 2002-08-29 2011-12-13 Stryker Corporation Device and method for treatment of a vascular defect
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US7344505B2 (en) * 2002-10-15 2008-03-18 Transoma Medical, Inc. Barriers and methods for pressure measurement catheters
US7544674B2 (en) * 2002-10-25 2009-06-09 Galderma S.A. Topical skin care composition
US7354574B2 (en) * 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
SI2218448T1 (sl) * 2002-12-13 2016-01-29 Durect Corporation Sistem za oralno dajanje zdravila, ki obsega tekoči nosilec materialov z visoko viskoznostjo
CA2510465A1 (en) * 2002-12-18 2004-07-08 Pain Therapeutics Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
EP1578398A2 (de) * 2002-12-19 2005-09-28 ALZA Corporation Stabilisierte nicht-wässrige einphasige gele und diese enthaltende zusammensetzungen zur verabreichung aus einer implantierbaren vorrichtung
DE10312346A1 (de) 2003-03-20 2004-09-30 Bayer Healthcare Ag Kontrolliertes Freisetzungssystem
US7776355B2 (en) 2003-07-03 2010-08-17 Medics Pharmaceutical Corporation Delivery system for topical medications
US20050025817A1 (en) * 2003-07-03 2005-02-03 Bhatia Kuljit S. Delivery system for topical medications
WO2005009406A1 (en) * 2003-07-18 2005-02-03 Hill Dermaceuticals, Inc. Topical skin care composition containing refined peanut oil
US20070140999A1 (en) * 2003-07-18 2007-06-21 Hill Dermaceuticals, Inc. Topical skin care composition containing refined peanut oil
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7083803B2 (en) * 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US20050181018A1 (en) * 2003-09-19 2005-08-18 Peyman Gholam A. Ocular drug delivery
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US20060099173A1 (en) * 2003-10-24 2006-05-11 Nancy Puglia Topical skin care composition
EP1711159B1 (de) * 2003-12-30 2013-03-20 Durect Corporation Festimplantate, welche ein block copolymer enthalten, für kontrollierte freisetzung von einer gnrh substanz
EP1708734A4 (de) * 2004-01-07 2009-06-17 Trimeris Inc Von hiv gp41 hr2 abgeleitete peptide und deren verwendung in der therapie zur hemmung der übertragung des humanen immundefizienzvirus
JP2005220333A (ja) * 2004-02-03 2005-08-18 Bmg Inc 生体内分解吸収性高分子及びその製造方法
WO2005074942A1 (en) * 2004-02-04 2005-08-18 Retmed Pty Ltd Slow release steroid composition
US9238127B2 (en) 2004-02-25 2016-01-19 Femasys Inc. Methods and devices for delivering to conduit
US8048086B2 (en) 2004-02-25 2011-11-01 Femasys Inc. Methods and devices for conduit occlusion
US8052669B2 (en) 2004-02-25 2011-11-08 Femasys Inc. Methods and devices for delivery of compositions to conduits
US8048101B2 (en) 2004-02-25 2011-11-01 Femasys Inc. Methods and devices for conduit occlusion
US20050256081A1 (en) * 2004-02-26 2005-11-17 Peyman Gholam A Tetracycline derivatives for the treatment of ocular pathologies
US20050192257A1 (en) * 2004-02-26 2005-09-01 Peyman Gholam A. Predictors for patients at risk for glaucoma from steroid therapy
ES2435398T3 (es) * 2004-04-08 2013-12-19 Eye Co Pty Ltd. Tratamiento de retinopatía exudativa con mineralocorticoides
US20050232876A1 (en) * 2004-04-19 2005-10-20 Robin Lynn Minga Skin care compositions
WO2005102303A2 (en) * 2004-04-21 2005-11-03 Advanced Ocular Systems Limited Antiprostaglandins for the treatment of ocular pathologies
US20050276855A1 (en) * 2004-06-15 2005-12-15 Milos Chvapil Composition and method using local application of lipophilic lathyrogens sustained release formulations
US7479289B2 (en) * 2004-07-02 2009-01-20 Medicis Pharmaceutical Corporation Stable cleanser compositions containing sulfur
US7655682B2 (en) * 2004-07-02 2010-02-02 Medicis Pharmaceutical Corporation Triple anti-irritant composition
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
ES2378671T3 (es) * 2004-09-17 2012-04-16 Durect Corporation Composición anestésica local prolongada que contiene SAIB
US9114162B2 (en) 2004-10-25 2015-08-25 Celonova Biosciences, Inc. Loadable polymeric particles for enhanced imaging in clinical applications and methods of preparing and using the same
US9107850B2 (en) 2004-10-25 2015-08-18 Celonova Biosciences, Inc. Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same
US20210299056A9 (en) 2004-10-25 2021-09-30 Varian Medical Systems, Inc. Color-Coded Polymeric Particles of Predetermined Size for Therapeutic and/or Diagnostic Applications and Related Methods
DE602005027229D1 (de) 2004-10-25 2011-05-12 Celonova Biosciences Germany Gmbh Beladbare polyphosphazenhaltige teilchen für therapeutische und/oder diagnostische anwendungen sowie herstellungs- und verwendungsverfahren dafür
US20060122152A1 (en) * 2004-12-03 2006-06-08 Peyman Gholam A Heparin for the treatment of ocular pathologies
US20060142234A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
EP1835885A1 (de) * 2004-12-23 2007-09-26 Durect Corporation Polymer-implantate, vorzugsweise mit einem gemisch aus peg und plg für die kontrollierte freisetzung eines gnrh
EP1904056B1 (de) * 2005-07-18 2009-04-29 Minu, L.L.C. Verwendung von Makroliden zur Wiederherstellung der Kornealempfindungen
US20070014760A1 (en) * 2005-07-18 2007-01-18 Peyman Gholam A Enhanced recovery following ocular surgery
US20070027105A1 (en) * 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
ES2381631T3 (es) * 2006-02-02 2012-05-30 Synageva Biopharma Corp. Péptidos inhibidores de la fusión del VIH con propiedades biológicas mejoradas
FR2898056B1 (fr) 2006-03-01 2012-01-20 Ethypharm Sa Comprimes resistant a l'ecrasement destines a eviter le detournement illicite
EP1854477B9 (de) 2006-03-16 2018-03-14 Dyax Corp. Peptid-Inhibitoren von Plasma Kallikrein zur Verwendung in der Behandlung von Augenerkrankungen
US7458953B2 (en) * 2006-06-20 2008-12-02 Gholam A. Peyman Ocular drainage device
EP2044142A2 (de) * 2006-06-29 2009-04-08 Medtronic, Inc. Poly(orthoester)polymere sowie herstellungs- und verwendungsverfahren dafür
GB0613333D0 (en) * 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
ES2820837T3 (es) * 2006-07-10 2021-04-22 Esbatech Alcon Biomed Res Unit Anticuerpos scFv que pasan las capas epitelial y/o endotelial
US20080160065A1 (en) * 2006-07-12 2008-07-03 Janet Anne Halliday Drug delivery polymer with hydrochloride salt of clindamycin
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
EP2117521B1 (de) * 2006-11-03 2012-06-27 Durect Corporation Transdermale abgabesysteme mit bupivacain
FR2910320B1 (fr) 2006-12-21 2009-02-13 Galderma Res & Dev S N C Snc Emulsion comprenant au moins un retinoide et du peroxyde de benzole
FR2910321B1 (fr) 2006-12-21 2009-07-10 Galderma Res & Dev S N C Snc Gel creme comprenant au moins un retinoide et du peroxyde de benzole
US20090022727A1 (en) 2007-01-26 2009-01-22 Alza Corp. Injectable, nonaqueous suspension with high concentration of therapeutic agent
JP2010523564A (ja) * 2007-04-03 2010-07-15 トリメリス，インコーポレーテッド 抗ウイルス性ペプチド治療薬の送達のための新規製剤
CN101677952B (zh) 2007-05-18 2012-12-05 杜雷科特公司 改进的贮库制剂
NZ581862A (en) 2007-05-25 2012-06-29 Tolmar Therapeutics Inc Injectable subcutaneous formulation comprising risperidone capable of forming a solid, microporous implant in a patient
JP2010540528A (ja) * 2007-09-25 2010-12-24 トリメリス，インコーポレーテッド 治療的抗ウイルス性ペプチドの新規合成方法
EP2219620B1 (de) * 2007-11-13 2017-07-19 Surmodics, Inc. Viskose terpolymere als arzneiabgabe-plattform
CA2706931C (en) * 2007-12-06 2015-05-12 Durect Corporation Oral pharmaceutical dosage forms
AU2013202707C1 (en) * 2007-12-06 2015-07-30 Durect Corporation Oral pharmaceutical dosage forms
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US8586103B2 (en) * 2008-02-08 2013-11-19 Foresee Pharmaceuticals, Llc Non-polymeric compositions for controlled drug delivery
AU2009212367B2 (en) * 2008-02-08 2013-08-01 Foresee Pharmaceuticals Co., Ltd. Composition for sustained release delivery of proteins or peptides
GB0804619D0 (en) * 2008-03-12 2008-04-16 Norbrook Lab Ltd A topical ectoparasiticide composition
US8956642B2 (en) * 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
US8475823B2 (en) * 2008-04-18 2013-07-02 Medtronic, Inc. Baclofen formulation in a polyorthoester carrier
US20090263456A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Methods and Compositions for Reducing Preventing and Treating Adhesives
EP2303393A4 (de) * 2008-05-07 2011-10-19 Obj Ltd Verfahren und gerät zur verstärkung der transdermalen diffusion
US10070888B2 (en) 2008-10-03 2018-09-11 Femasys, Inc. Methods and devices for sonographic imaging
US9554826B2 (en) 2008-10-03 2017-01-31 Femasys, Inc. Contrast agent injection system for sonographic imaging
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US8822546B2 (en) * 2008-12-01 2014-09-02 Medtronic, Inc. Flowable pharmaceutical depot
WO2010077732A2 (en) * 2008-12-09 2010-07-08 Aether Medical Llc Implantable analgesic
US20100168807A1 (en) * 2008-12-23 2010-07-01 Burton Kevin W Bioactive terpolymer compositions and methods of making and using same
US8951546B2 (en) * 2008-12-23 2015-02-10 Surmodics Pharmaceuticals, Inc. Flexible implantable composites and implants comprising same
US9415197B2 (en) * 2008-12-23 2016-08-16 Surmodics, Inc. Implantable suction cup composites and implants comprising same
US9480643B2 (en) 2008-12-23 2016-11-01 Surmodics Pharmaceuticals, Inc. Implantable composites and implants comprising same
US8974808B2 (en) * 2008-12-23 2015-03-10 Surmodics, Inc. Elastic implantable composites and implants comprising same
US20120207770A1 (en) 2009-10-14 2012-08-16 Nanyang Technological University Antiproliferative agent
JP5809251B2 (ja) 2010-05-25 2015-11-10 インターナショナル・サイエンティフィック・プロプライエタリー・リミテッド 口腔ケア製品の送達
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
US9463330B2 (en) 2010-06-17 2016-10-11 International Scientific Pty Ltd Delivery of skin care products
WO2012030819A1 (en) 2010-08-30 2012-03-08 Surmodics Pharmaceuticals, Inc. Terpolymers as pressure-sensitive adhesives
PL2626092T3 (pl) * 2011-04-01 2016-02-29 Zhuhai Ortus Biotechnology Co Ltd Medyczny wchłanialny hemostatyczny materiał do ran z obnażeniem kości i sposób jego wytwarzania
EP2782590A4 (de) * 2011-11-23 2016-08-03 Durect Corp Biologisch abbaubare und mittels strahlung sterilisierte arzneimittelabgabezusammensetzungen
KR102326359B1 (ko) 2012-05-18 2021-11-12 제넨테크, 인크. 고농도 모노클로날 항체 제제
US10220093B2 (en) 2013-02-28 2019-03-05 Mira Pharma Corporation Long-acting semi-solid lipid formulations
KR101768843B1 (ko) 2013-02-28 2017-08-17 미라 파마 코포레이션 주사가능 장기-작용 국소 마취제 반고체 제형 및 이의 조성물
BR112015022023B1 (pt) 2013-03-11 2022-12-06 Durect Corporation Composição de liberação controlada injetável compreendendo transportador líquido de alta viscosidade
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
EP2968111B1 (de) 2013-03-15 2024-05-01 Heron Therapeutics, Inc. Zubereitung von einem polyorthoesters und einem aprotischen lösungsmittels
EP2970253A4 (de) 2013-03-15 2016-11-02 Durect Corp Zusammensetzungen mit thixotropie und verbesserter auflösungsreproduzierbarkeit sowie stabilität
AU2014233453A1 (en) 2013-03-15 2015-10-01 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
WO2015123734A1 (en) * 2014-02-21 2015-08-27 The University Of Sydney Liquid carrier materials
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
EP3154552B1 (de) 2014-06-11 2021-03-24 International Scientific Pty Ltd Vorrichtung und verfahren zur behandlung oder prävention von gelenkverschleiss
WO2016079331A1 (en) * 2014-11-21 2016-05-26 Technical University Of Denmark Gel formulations for enhancing the effect of radiotherapy
EP3220887A1 (de) * 2014-11-21 2017-09-27 Technical University of Denmark Gelformulierungen zur lokalen arzneistoffabgabe
CA3023928A1 (en) 2016-05-20 2017-11-23 Technical University Of Denmark Palpable marker composition
CA3028450A1 (en) 2016-07-06 2018-01-11 Durect Corporation Oral dosage form with drug composition, barrier layer and drug layer
US11752099B2 (en) * 2017-03-27 2023-09-12 W. L. Gore & Associates, Inc. Injectable and biodegradable polymer formulations for controlled release of bioactive agents
SG11201909478UA (en) 2017-04-24 2019-11-28 Cocrystal Pharma Inc Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
US11890395B2 (en) 2017-06-16 2024-02-06 Avery Therapeutics, Inc. Three dimensional tissue compositions and methods of use
US11426418B2 (en) 2017-12-06 2022-08-30 Mira Pharma Corporation Injectable long-acting semi-solid gel formulations
US10561606B2 (en) 2017-12-06 2020-02-18 Mira Pharma Corporation Injectable long-acting local anesthetic semi-solid gel formulations
MX2021000917A (es) 2018-07-27 2021-06-23 Cocrystal Pharma Inc Derivados de pirrolo[2,3-b]piridina como inhibidores de la replicación del virus de la gripe.
JP7472108B2 (ja) 2018-09-10 2024-04-22 コクリスタル ファーマ，インコーポレイテッド ピリドピラジン系及びピリドトリアジン系インフルエンザウィルス複製阻害剤
MX2021004215A (es) 2018-10-17 2021-07-15 Cocrystal Pharma Inc Combinaciones de inhibidores de la replicación del virus de la gripe.
WO2020112716A1 (en) 2018-11-26 2020-06-04 Cocrystal Pharma, Inc. Inhibitors of influenza virus replication
WO2020249801A1 (en) 2019-06-12 2020-12-17 Technical University Of Denmark Dissacharide formulations for controlled drug release
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
US20230151034A1 (en) 2020-03-17 2023-05-18 Cocrystal Pharma, Inc. Peptidomimetic n5-methyl-n2-(nonanoyl-l-leucyl)-l-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds as inhibitors of norovirus and coronavirus replication
AU2021254045A1 (en) 2020-04-10 2022-10-13 Cocrystal Pharma, Inc. Inhibitors of norovirus and coronavirus replication
TW202321196A (zh) 2021-08-03 2023-06-01 美商共結晶製藥公司 冠狀病毒抑制劑
EP4282435A1 (de) 2022-05-23 2023-11-29 Danmarks Tekniske Universitet Formulierungen von api's und hilfsstoffen in icells durch hydrophobe ionenpaarung

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2931802A (en) 1958-04-30 1960-04-05 Eastman Kodak Co Mixed esters of glucose and sucrose
GB1088992A (en) 1963-09-19 1967-10-25 Squibb & Sons Inc Protective dressings
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US3743398A (en) 1971-03-22 1973-07-03 Eastman Kodak Co Motion picture projector
NO139560C (no) 1972-04-29 1979-04-04 Takeda Chemical Industries Ltd Analogifremgangsmaate til fremstilling av terapeutisk virksomme nonapeptidamid-derivater
CA1030526A (en) 1973-11-01 1978-05-02 Samuel Wilkinson Biologically active amides
DE2438352A1 (de) 1974-08-09 1976-02-26 Hoechst Ag Peptidcyclopropylamide mit lh-rh/fshrh-wirkung
DE2438350C3 (de) 1974-08-09 1979-06-13 Hoechst Ag, 6000 Frankfurt Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
JPS55154991A (en) * 1979-05-23 1980-12-02 Hisamitsu Pharmaceut Co Inc Beta-d-fructopyranoside derivative
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
DE3716302C2 (de) * 1987-05-15 1996-02-01 Henkel Kgaa Verbesserte resorbierbare Knochenwachse und ihre Verwendung
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4622219A (en) 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4891225A (en) 1984-05-21 1990-01-02 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
IT1198449B (it) 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
US5391381A (en) 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US5350741A (en) 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
JPH0296516A (ja) 1988-09-29 1990-04-09 Dainippon Pharmaceut Co Ltd 粒剤およびその製造方法
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5324520A (en) 1988-12-19 1994-06-28 Vipont Pharmaceutical, Inc. Intragingival delivery systems for treatment of periodontal disease
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
IT1240643B (it) 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano
US5149543A (en) 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
EP0539559A1 (de) 1991-04-03 1993-05-05 Eastman Kodak Company Maske mit hoher Dauerhaftigkeit für die Trockenätzung von GaAs
JP3313124B2 (ja) 1991-07-31 2002-08-12 森下仁丹株式会社 親水性物質を内容物とするシームレスカプセルおよびその製法
US5487898A (en) 1991-08-26 1996-01-30 Abbott Laboratories Compositions and method for the sublingual or buccal administration therapeutic agents
YU87892A (sh) 1991-10-01 1995-12-04 Eli Lilly And Company Lilly Corporate Center Injektibilne formulacije produženog otpuštanja i postupci za njihovo dobijanje i primenu
AU2605592A (en) 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
CA2121674C (en) 1991-10-21 2003-05-06 Timothy E. Trigg Biocompatible implant for the timing of ovulation in mares
ATE236655T1 (de) * 1993-01-06 2003-04-15 Kinerton Ltd Ionische molekularkonjugate von bioabbaubaren polyestern und bioaktiven polypeptiden
US5340572A (en) 1993-02-08 1994-08-23 Insite Vision Incorporated Alkaline ophthalmic suspensions
NZ263410A (en) 1993-03-17 1997-05-26 Minnesota Mining & Mfg Pharmaceutical aerosol containing diol-diacid derived dispersing aid
ES2122261T3 (es) 1993-03-17 1998-12-16 Minnesota Mining & Mfg Formulacion de aerosol que contiene un adyuvante de dispersion derivado de un ester, una amida o un mercaptoester.
DE4322826A1 (de) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmazeutisches Präparat
JP3257750B2 (ja) * 1993-07-20 2002-02-18 エチコン・インコーポレーテツド ε−カプロラクトンおよびラクチドの液状コポリマー
JPH07112940A (ja) 1993-08-26 1995-05-02 Takeda Chem Ind Ltd 徐放性非経口投与製剤およびその製造方法
JPH07115901A (ja) 1993-10-28 1995-05-09 Fuji Bibaretsuji:Kk ドコサヘキサエン酸高含有乳化組成物及び飲料
EP0739210B1 (de) 1993-12-29 2002-07-24 Matrix Pharmaceutical, Inc. Zusammensetzung für lokale freigabe von zytostatika
EP0754032B1 (de) 1994-04-08 2001-12-05 Atrix Laboratories, Inc. Flüssige mittel zur wirkstoffabgabe
US5599852A (en) * 1994-10-18 1997-02-04 Ethicon, Inc. Injectable microdispersions for soft tissue repair and augmentation
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
PT1006935E (pt) 1995-06-07 2005-06-30 Durect Corp Sistema de entrega controlada liquido de alta viscosidade
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
JPH10115901A (ja) 1996-10-09 1998-05-06 Noritsu Koki Co Ltd 写真現像処理装置
EP0949905B1 (de) 1996-12-20 2001-07-18 Alza Corporation Injizierbare depotgelzubereitung und herstellungsverfahren
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
DE19714765A1 (de) * 1997-04-10 1998-10-15 Merck Patent Gmbh Verwendung von niedermolekularen, oligomeren Estern von alpha-Hydroxysäuren und/oder aromatischen o-Hydroxysäuren in kosmetischen Formulierungen
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6051558A (en) 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
DE19858891A1 (de) * 1998-12-19 2000-06-21 Merck Patent Gmbh Verbesserte Knochensiegel
AU5025300A (en) 1999-06-18 2001-01-09 Southern Biosystems, Inc. Compositions for controlled release of the hormone gnrh and its analogs

Also Published As

Publication number Publication date
DE60023520T2 (de) 2006-07-27
JP2009143935A (ja) 2009-07-02
JP2003508449A (ja) 2003-03-04
AU2005205766A1 (en) 2005-09-29
US6413536B1 (en) 2002-07-02
AU2009201321A1 (en) 2009-04-23
EP1212092A2 (de) 2002-06-12
ATE307611T1 (de) 2005-11-15
ES2254219T3 (es) 2006-06-16
US7053209B1 (en) 2006-05-30
CA2382540C (en) 2009-06-16
AU7331900A (en) 2001-03-26
WO2001015734A2 (en) 2001-03-08
JP4276807B2 (ja) 2009-06-10
CA2382540A1 (en) 2001-03-08
US20060210599A1 (en) 2006-09-21
WO2001015734A3 (en) 2001-09-13
EP1212092B1 (de) 2005-10-26

Similar Documents

Publication Publication Date Title
DE60023520D1 (de) Flüssiges hochvisköses system mit gesteuerter freisetzung und medizinische oder chirurgische vorrichtung
WO2004052336A3 (en) High viscosity liquid controlled delivery system and medical or surgical device
ATE316786T1 (de) Behandlung von mukositis
BR9405798A (pt) Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
GEP20053427B (en) Pharmaceutical Compositions Providing Enhanced Drug Concentrations
ATE288258T1 (de) Biodegradierbare polymerzusammensetzung
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
DE69727158D1 (de) Pharmazeutische zusammensetzungen enthaltend eine mischung von selbstvernetzter und nichtselbstvernetzter hyaluronsäure zur behandlung von arthropathien
EP0804595A4 (de)
ATE74752T1 (de) Biologisch erodierbares system mit gesteuerter freisetzung des arzneiwirkstoffes.
FI962154A0 (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
TR200102648T2 (tr) Büyümeyi destekleyen bileşimler
WO2007062060A3 (en) Methods and compositions using substance p to promote wound healing
ATE424848T1 (de) Pharmazeutische zusammensetzungen für die kontrollierte freigabe von biologischen wirkstoffen
ATE396967T1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
DE60231862D1 (de) Erodierbare polymere zur injektion
ATE311373T1 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
ATE253820T1 (de) Wirkstoffhaltige komposition sowie deren herstellung und verwendung
TW200635616A (en) Organic compounds
ATE505508T1 (de) Arzneistoffzufuhrvorrichtung, die einen wirkstoff enthält, und verfahren zur freisetzung eines wirkstoffs aus einer arzneistoffzufuhrvorrichtung
SE9603480D0 (sv) Beredningsform för svårlösliga läkemedel
PT1229909E (pt) Entrega transdermica de lasofoxifeno
EA200200914A1 (ru) Система контроля дозирования для однократного ежедневного приема назначенного ципрофлоксацина
DE602006010111D1 (de) Pharmazeutische formulierung zur behandlung von osteoarthritis mit clodronsäure und hyaluronsäure
ATE85213T1 (de) Einen wirkstoff und ein in wasser quellendes polymer enthaltendes arzneimittel.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition